By a News Reporter-Staff News Editor at Biotech Week -- Liventa Bioscience (formerly AFcell Medical) and Cryoport, Inc. (OTC:CYRX) announced a major strategic alliance aimed at serving the many points of orthopedic care delivery with Liventa's cell-based, advanced biologics tissue forms. The exclusive agreement combines Cryoport's proprietary, purpose-built cold chain logistics solutions for cell-based and advanced biologic tissue forms with Liventa Bioscience's distribution capability to "point-of-use" US-based orthopedic care providers (see also Cryoport, Inc.).
In 2013, approximately $230 million of cell-based biologic products for orthopedic uses were shipped to hospitals and other clinics using dry ice and hospital-based cryogenic freezers. Cryoport's solution, based on its Cryoport Express® liquid nitrogen dry vapor shippers, eliminates the need for dry-ice shipping and hospital-based cryogenic freezers.
As a result of this alliance, Liventa will now be able to provide Cryoport Express® Shippers and Cryoport's Logistics Management Platform (the Cryoportal™) to all advanced biologics suppliers within the orthopedic arena. This logistics system coupled with the small portable cold chain containers, will enable Liventa to better serve small or mobile clinics, pharmacies, family practice and orthopedic specialty care providers. Surgical centers and hospitals also benefit from better logistics and the elimination of issues surrounding dry ice transport and storage.
Liventa's Chief Executive Officer, Robin Young, said, "After careful research, we concluded that Cryoport's logistics solutions, which include both shipping and information logistics, was by far the most advanced solution available for both our AmnioClear® cryopreserved tissue products and other cryopreserved cellular products. Cryoport's system opens up every corner of the orthopedic industry to advanced biologic tissue and cell forms." No Dry Ice or Installed Freezers Cryoport's patented portable cryogenic logistics solutions substantially reduce the "process nuisance" as well as the cost of ordering, using, and storing cell-based biologic products at validated cryogenic temperatures. Cryoport's solution eliminates the need for hazardous dry ice or capital investment in cryogenic freezers.
Cryoport's Chief Executive Officer, Jerrell Shelton, said, "Liventa Bioscience comes at a very important time in this early stage of applied stem cell therapy with its AmnioClear® platform. We are proud to be a strategic partner providing our unparalleled temperature controlled logistics solutions to support this revolutionary company. This partnership is positioned to bring Liventa's AmnioClear® products and other advanced biologic solutions to an estimated 108 million patients annually who suffer from knee, hip, extremity, spine and other orthopedic disabilities." Bridging Two Major Orthopedic Trends Cryoport's logistics solutions plus Liventa's distribution bridges two powerful trends in orthopedics - the increasingly diversified orthopedic point-of-care delivery and the rising use of cell-based advanced biologics.
Orthopedic care is now provided in offices of the family practitioner, the internist, the orthopedist's ambulatory surgical center, the pain management clinic, the pharmacy, the physical medicine specialist, the rheumatologist, the sports medicine clinic and the chiropractor. Among established orthopedic programs, hospital networks are the fastest growing practice sector in outpatient orthopedic care.
Most of these service providers do not have cryogenic freezers or the infrastructure to handle cell-based tissue forms. Even when there is a cryogenic freezer, space is at a premium. This new strategic agreement opens up the entire range of orthopedic markets and care providers to cell-based, advanced biologic tissue forms intended to promote healing and provide relief not available through other treatments.
Richard Rathmann, Chairman of the Board of Cryoport, said, "Cell-based therapies and tissue forms such as Liventa's AmnioClear® are providing a sea change in medicine just as Amgen and biotechnology did 30 years ago. This alliance reflects Cryoport's critical role as a solutions provider in the preservation and safe transport of these novel, life-altering therapies." About Cryoport, Inc.Cryoport provides leading edge frozen logistics solutions to the life sciences industry through the combination of purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. Its competencies range from skilled, total turnkey management of the entire life sciences cold chain logistics process to complex total management solutions for outsourced cold chain logistics.
Its packaging, built around its Cryoport Express® liquid nitrogen dry vapor shippers, is validated to maintain a constant -150°C temperature for a 10-plus day dynamic shipment duration. Its information technology boasts a Cryoportal™ Logistics Management Platform which manages the entire shipment process, including initial order input, document preparation, customs clearance, integrator/courier management, shipment tracking, issue resolution, and delivery. Cryoport uses recyclable and reusable components providing an environmentally friendly solution. Cryoport solutions can record the "chain of condition" and "chain of custody" for shipments thereby meeting the exacting requirements for scientific work and for regulatory purposes. For more information, visit www.cryoport.com About Liventa Bioscience Liventa Biosciences, formerly AFcell Medical, Inc. is a commercial stage biotechnology company focused on bringing advanced biologics to market. Its innovative allograft tissue forms come from living donors and are available through independent distribution. Liventa is currently offering or is in the process of developing a number of advanced orthopedic biologics. These products include human collagen membrane sheets derived from placental tissues, flowable wound coverings, synovial fluid transplants and innovative new soft tissue repair implants. In addition to its strategic alliance with Cryoport, Liventa is also a key strategic partner with one of the premier independent distributor organizations in the United States, Crosslink Orthopaedics.
Keywords for this news article include: Biotechnology, Hospital, Chemicals, Chemistry, Bioscience, Biologicals, Cryoport Inc., Information Technology.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC